Truist analyst Gregory Renza initiated coverage of Abivax (ABVX) with a Buy rating and $140 price target Following a second-half re-rate from phase 3 induction data in ulcerative colitis, investors are focused on obefazimod’s increasing value proposition and set-up for key phase 3 UC maintenance data in Q2 of 2026 and phase 2b induction topline in Crohn’s disease coming the second half of 2026, the analyst tells investors in a research note. Obefazimod represents an unusual mechanism of action, which the firm views as being backed by preclinical and clinical evidence indicating broad immunological effects, Truist added.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABVX:
- Caterpillar upgraded, Elf Beauty downgraded: Wall Street’s top analyst calls
- Positive Outlook for Abivax SA: Obefazimod’s Potential in Crohn’s Disease Drives Buy Rating
- Abivax initiated with an Outperform at Wolfe Research
- Abivax announces patient-reported outcomes from ABTECT trial
- Abivax initiated with an Overweight at Barclays